HOUSTON, April 22, 2019 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors, today announced
it will host a conference call to discuss its significant discovery
for lung cancer, FDA Fast Track Designation and recent corporate
events. The call will be at 4:30 p.m. ET on Wednesday, April 24, 2019.
Participants can dial (800) 860-2442 or (412) 858-4600 to access
the conference call, or can listen via a live webcast, which is
available in the Investor Relations section of the Company's
website at www.moleculin.com. The Company will field live
questions from equity analysts in a Q&A segment of this
call. Participants may submit questions in advance for the
Company to address in the Q&A segment by sending them to
info@moleculin.com. A webcast replay will be available in the
Investors section of the Company's website
at www.moleculin.com for 90 days. A teleconference replay
will be available at (877) 344-7529 or (412) 317-0088, confirmation
code 10130980, through May 1,
2019.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors. The
Company's clinical stage drugs are: Annamycin, a Next Generation
Anthracycline, designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, targeting
brain tumors, pancreatic cancer and AML, and WP1220, an analog to
WP1066, for the topical treatment of cutaneous T-cell lymphoma.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional
Immune/Transcription Modulators, as well as compounds capable of
Metabolism/Glycosylation Inhibition.
For more information about the Company, please visit
https://www.moleculin.com.
Contacts
Joe Dorame,
Robert Blum or Joe Diaz
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-conference-call-to-discuss-significant-discovery-for-lung-cancer-and-fda-activity-on-wednesday-april-24-2019-300835421.html
SOURCE Moleculin Biotech, Inc.